Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer

This is a multi-center clinical study enrolling up to 12 participants . The primary objective of the study is to evaluate the safety of Alpha DaRT for the treatment of locally recurrent prostate cancer . The secondary objectives of the study is to evaluate the efficacy of the Alpha DaRT sources in locally recurrent prostate cancer patients assessed by biochemical and clinical evaluation of disease progression as well as overall survival

NCT Number	NCT07290998
Lead Sponsor	Alpha Tau Medical LTD.
Conditions	Prostate Cancer, Recurrent Prostate Cancer, Locally Recurrent Prostate Cancer
Enrollment	12 participants
Start Date	2026-05
Primary Completion	2028-05 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2026-04-06